The second curve of a park

Editor's Note: Why We Pay Attention to Yunke Zhigu

China has many industrial parks. The ones that truly deserve media attention are not usually the ones that boast the most about size, investment, and location, but rather the ones that can provide support for businesses during their most difficult phases.

GFM.News published this article about Changsha Golden Innovation Park and Yunke Zhigu Pharmaceutical Manufacturing Park because we see an important industry issue: Chinese biomedical and medical device companies are moving towards a deeper stage of industrialization. After companies have the technology, products, and market vision, the next step is to face pilot testing, production, registration, compliance, delivery, and capacity expansion. These stages are often quiet, but they are the most likely to determine whether a company can truly grow.

Many industrial parks will introduce land, factory buildings, policies, and transportation. These conditions are important, but once medical device companies actually move in, they will quickly encounter more specific problems: Is the ceiling height sufficient? Can the load-bearing capacity support the equipment? How to modify cleanroom and sewage systems? Are the power supply and personnel/material flow routes reasonable? Can the quality system and registration process be smoothly integrated? These seemingly minor engineering and service details often affect the product launch timeline.

(Image caption) The modern production space in Yunke Zhigu Pharmaceutical Manufacturing Park showcases the pilot-scale, compliant production, and large-scale delivery capabilities provided by central cities in the biomedical industrialization stage.

Yunke Zhigu's distinctiveness lies in its expansion beyond the incubation services built up over many years by the Golden Innovation Park, extending into more demanding and specialized pharmaceutical manufacturing scenarios. It presents a valuable case study: how central Chinese cities can support the second curve of industrialization for biomedical companies.

GFM.News included this article in its "Healthcare Sovereignty" section because healthcare sovereignty ultimately boils down to concrete capabilities. It requires stable pilot-scale platforms, compliant production facilities, quality traceability, registration services, supply chain support, and the ability to deliver at scale. Without these foundations, even the best technology will struggle to become a continuously available product.

We focus on Yunke Zhigu because we hope to observe the next stage of transformation of industrial parks in China through a specific case: how space supply can be upgraded to industrial delivery, how local investment promotion can move towards enterprise services, and how park projects can become industrialization models that can be studied, compared, and learned from.

If an industrial park can help businesses avoid relocation, unnecessary detours, and prevent them from falling into avoidable pitfalls, its value already exceeds its rent and floor space. This is why this article is worth reading.

Jeff Morgan, Editor-in-Chief of GFM News

—————————————————————————————————————————

On China's industrial map, many industrial parks are accustomed to describing themselves in the same language.

How many acres of land, how many square meters of factory buildings, how many hundred million yuan of investment, how many minutes from the high-speed rail station, how many kilometers from the highway exit, how many enterprises it can support in the future, and how much output value it is expected to generate. These figures are important, but if you talk about them too much, it's easy to lose touch with them.

The truly interesting industrial parks are often not defined by the number of buildings they have, but by their location at a turning point in a city's industry, where they have taken on the most difficult part of the journey for a group of companies.

(Image caption ) Yunke Zhigu Pharmaceutical Intelligent Manufacturing Park is located in the High-speed Rail West section of Hunan Xiangjiang New Area. Relying on the national-level incubation foundation of Changsha Golden Innovation Park, it provides industrialization space for enterprises in biomedicine, medical devices, electronic information and advanced manufacturing.

Changsha Golden Innovation Park and its second-phase project, Yunke Zhigu Pharmaceutical Intelligent Manufacturing Park, deserve to be re-examined from this perspective.

Golden Innovation Park is not an industrial real estate that suddenly appeared. It is more like an old foundation in the industrial growth of Changsha Hexi: from business incubation and technology enterprise services to policy application, enterprise cultivation, and talent and financial connection, this park has accumulated a capability over the years that is not easily shown in renderings - enabling enterprises to grow from small to large, enabling ideas to come to fruition, and enabling entrepreneurs to avoid being stuck in the system and process.

Yunke Zhigu Medical Intelligent Manufacturing Park is a new proposition built on this old foundation.

It no longer just serves general science and technology innovation enterprises, but attempts to provide space and services closer to the deep waters of industrialization for enterprises in biomedicine, medical devices, in vitro diagnostics, rehabilitation equipment, and advanced manufacturing. This is also the difference between it and general factory projects: what it really wants to answer is not "where do enterprises rent space", but "how enterprises move from R&D to pilot production, from pilot production to production, and from production to the market".

This issue is becoming increasingly global.

The hardest path isn't at the exhibition.

The global medical device market continues to grow. An aging population, chronic disease management, precision diagnostics, rehabilitation care, home healthcare, AI-powered medicine, in-vitro diagnostics, and surgical robots are all driving this industry's continued expansion. While estimates of market size vary slightly among different research institutions, they all point to one common direction: medical devices remain one of the most promising industries for the next decade.

However, the real pressure on businesses is also increasing at the same time.

The journey of a medical device from the laboratory to the hospital is not a smooth one. The prototypes at trade shows can be impressive, the market potential presented in roadshows can be compelling, and the story told to investors can be compelling. But once offstage, the problems facing companies quickly become concrete: Is the registration documentation complete? Are the production facilities compliant? Is the quality system closed-loop? Is the clinical evidence sufficient? Is the supply chain stable? Can the costs withstand centralized procurement and market competition? And once the products are mass-produced, are they consistent, reliable, and traceable?

Many companies are not lacking in technology or market access, but rather stuck on that silent path between laboratories and hospitals.

This path is called industrialization.

This issue is particularly relevant for Chinese medical device companies. While the Chinese market remains large, price pressures, regulatory requirements, and changing distribution channels are all increasing the difficulty of survival for these companies. Public reports show that in the first three quarters of 2025, China's total medical device exports reached US$37.007 billion, a year-on-year increase of 5.61%; exports to countries participating in the Belt and Road Initiative accounted for over 40%. This means that going global is no longer just a strategic choice for leading companies; for a significant number of Chinese medical device companies, it is becoming an unavoidable question under the pressure of growth.

But going global is not as simple as just shipping products out. For products to reach overseas markets, a stable industrial base must first be established domestically. Production must be stable, quality must be stable, the supply chain must be stable, the cost structure must be stable, and after-sales service capabilities must keep up. If the domestic stage is not stable, the overseas market will only amplify the shortcomings.

Thus, a seemingly ordinary question becomes important: Where exactly do companies complete industrialization?

(Image caption ) A real view of Yunke Zhigu Industrial Park. For medical device companies, the value of the park lies not only in its building area, but also in its ability to meet the continuous needs of R&D, pilot production, manufacturing, environmental impact assessment, and compliance upgrades.

Changsha's value is more than just cost.

China's medical device industry has historically grown along the coast and in first-tier cities. Shenzhen boasts an electronics and hardware supply chain, Shanghai possesses high-end medical resources and capital density, Suzhou has accumulated expertise in in-vitro diagnostics and consumables, and Hangzhou has established an advantage in digital health and platform-based enterprises. The positions of these locations are not easily replaced.

However, once a company moves from R&D to pilot production, and from pilot production to mass production, the pressure of cost and space will gradually become apparent. The headquarters can be located in a first-tier city, R&D can be located in a first-tier city, and the market window can also be located in a first-tier city; but pilot production, assembly, testing, warehousing, some production and supply chain coordination may not always be suitable to be located in the most expensive areas.

This is precisely why central cities are being rediscovered.

However, Changsha's value cannot be simply described as "cheap." Cheapness is merely a price; industrialization requires a system. If a place lacks upstream and downstream enterprises, knowledgeable people, testing and service platforms, and policy and financial support, even with low rents, businesses may incur higher hidden costs.

What truly deserves attention in Changsha is that it is no longer a blank slate in the fields of biomedicine and medical devices.

Sinocare has long been deeply involved in the field of blood glucose management, while Sansure Biotech has accumulated global market experience in molecular diagnostics and nucleic acid testing. Traditional pharmaceutical companies such as Jiuzhitang represent another lineage of the pharmaceutical industry. These companies are not just a few brands; around them, sensors, reagents and consumables, cold chain logistics, medical software, packaging supply, clinical cooperation, regulatory services, quality personnel, and engineers have gradually emerged.

An industrial ecosystem is never drawn on a blueprint. It is built up by individual companies, by groups of engineers, and by countless registrations, tests, production runs, and market validations.

Xiangjiang New Area is one of the most important areas along this industrial chain. Public data shows that the total output value of biomedicine in Xiangjiang New Area has exceeded 90 billion yuan, with more than 2,100 companies in the industrial chain. The "Changsha Bio-economic Development Three-Year Action Plan (2023-2025)" also places Xiangjiang New Area in an important position, proposing to build an industrial system with traditional Chinese medicine and medical devices as the core, and chemical drugs, biological drugs, pharmaceutical logistics and high-end services as support.

The value of these figures lies not in their astonishment, but in illustrating one thing: the Changsha Hexi area has the potential to attract more biomedical companies to establish industrial operations.

The stories of Golden Innovation Park and Yunke Smart Valley unfolded on this land.

Golden Startup Park: The Regeneration of an Old Foundation

The problem with many industrial parks is that they only have buildings, but no time for development.

Buildings can be completed in a few years, and investment brochures can be prepared quickly, but business service capabilities are not a short-term project. It requires time, interaction with businesses, understanding where they are most likely to encounter problems, and comprehending the delicate relationship between government policies, financial institutions, the talent market, and business growth.

The value of the Golden Innovation Park lies in the fact that it is not a newly launched project.

Over the years, as a national-level science and technology business incubation platform, it has accumulated capabilities in business incubation, business registration services, policy application, talent matching, financial support, and project cultivation. These capabilities may not be as eye-catching as a building, but they are the things that businesses can most easily feel when they set up shop there.

When a company first arrives, it needs registration, premises, renovation, recruitment, and daily operations. As the company grows, it faces challenges related to high-tech enterprises, specialized and innovative enterprises, intellectual property rights, policy projects, and financing. Further along, it needs to consider expansion, compliance, branding, market access, and capital pathways. A park that truly understands its businesses isn't just enthusiastic at the time of signing, but rather knows where the next hurdle lies at different stages of the company's growth.

This is the foundation that the Golden Innovation Park left for Yunke Zhigu.

Yunke Zhigu doesn't start from scratch in pharmaceutical manufacturing; rather, it builds upon existing incubation experience, enterprise service systems, and urban industrial foundations, taking a step towards more crucial industrialization aspects. This step is its true significance.

Yunke Zhigu: Turning Factory Buildings into Stepping Stones for Industrialization

Yunke Zhigu Pharmaceutical Manufacturing Park is located in the High-speed Rail West section of Xiangjiang New Area, relying on the second phase of Changsha Golden Innovation Park. Public information shows that the park has a total construction area of approximately 300,000 square meters, and is planned to include R&D offices, pilot plants, multi-story standard factory buildings, enterprise townhouses, independent spaces, and talent apartments. The park's investment direction covers biomedicine, medical devices, electronic information, advanced manufacturing, and productive services.

Simply listing this information won't make people stop and read it. Too many industrial parks in China can list their area, investment, and location. What Yunke Zhigu should truly be understood about is whether it can transform these spaces into stepping stones for business growth.

(Image caption ) For medical device companies, floor height, load-bearing capacity, freight elevators, passenger and material flow, smoke and exhaust, and wastewater treatment are not just engineering parameters, but also part of the efficiency of product registration, compliant production, and production launch.

Medical device companies are most afraid of relocating.

In the early stages of R&D, a small space is sufficient; as the product enters pilot production, space becomes insufficient, necessitating relocation; and when preparing for large-scale production, it's discovered that the new site's cleanliness, wastewater treatment, load-bearing capacity, power supply, and workflow are unsuitable, requiring another relocation. Each relocation necessitates a complete overhaul of the address, equipment, quality system, employee commuting arrangements, supply chain arrangements, and regulatory documents. For ordinary companies, relocation is a management cost; for medical device companies, it can alter the product launch timeline.

Therefore, the areas of 450 square meters, 800 square meters, 1200 square meters, and 1600 square meters are not just apartment sizes, but rather steps on the growth curve of a company.

The first floor is 7.2 meters high, the second floor is 4.5 meters high, the load-bearing capacity is 600 to 800 kilograms per square meter, the freight elevator is 3 tons, the flow of people and goods is separated, the sewage treatment is provided, the space for clean workshop is reserved, and the exhaust duct is provided. These seemingly boring industrial parameters are connected to the things that enterprises care about most: whether the equipment can be put into the site, whether the production line can be set up, whether the environment can be controlled, whether the environmental impact assessment can be approved, whether the inspection can reduce rework, and whether the products can be put into production on schedule.

A good industrial space is quiet. It doesn't need slogans plastered on every wall; it just needs to minimize problems when businesses need them most.

If Yunke Zhigu wants to attract international investment from biomedical companies, it should focus not on "how many square meters we have", but on "whether we can help companies avoid detours here".

The real investment attraction begins after the signing of the contract.

For medical device companies, signing a contract is just the beginning.

A company preparing to manufacture Class II medical devices doesn't really need a policy list; it needs someone to remind it that site renovations, quality systems, registration documents, testing arrangements, and production licenses cannot proceed independently but must be prioritized. If the order is wrong, rework is likely to follow.

A company that manufactures in vitro diagnostics products needs more than just a simple "we can assist with the process." Before signing a contract, it needs to know which aspects of the laboratory layout, sample flow, waste disposal, temperature and humidity control, cleanliness requirements, and cold chain conditions are feasible within the existing space, which require modifications, and which, if not clearly defined from the outset, will inevitably result in a double loss of money and time.

If a company from another region is planning to move some of its production to Changsha, it's not just looking at a rendering. It's considering whether the engineers are willing to stay, whether the living facilities are adequate, whether there are readily available suppliers of consumables and spare parts nearby, whether the government's response time is predictable, and whether banks and funds are willing to understand the industry.

When it comes to attracting investment to industries, the final question is whether these seemingly trivial issues can be properly addressed.

This is also where Yunke Zhigu needs to be tested. It has the incubation service foundation of a golden startup park and hardware space for pharmaceutical intelligent manufacturing. However, there is still a long way to go from investment promotion rhetoric to enterprise delivery. What can truly gain the trust of enterprises is not "we can provide services," but whether the park can provide a number of case studies to prove that it has accompanied enterprises through the specific processes of registration, transformation, pilot testing, production, expansion, and policy application.

In this sense, the watershed in the competition among industrial parks lies not in attracting investment, but in delivering the finished product.

(Image caption ) Construction site of Phase II of Yunke Zhigu Medical Intelligent Manufacturing Park. The western plot of the park will add approximately 35,000 square meters of factory buildings, addressing the space needs of medical device and precision manufacturing companies as they move from pilot production to large-scale production.

Internationalization is not about translating investment brochures

Today, many places are talking about international investment promotion. But true international investment promotion is not about translating Chinese materials into English, nor is it about taking more beautiful photos of the park and adding a few words like "global," "innovation," and "future."

International investment promotion is first and foremost about the ability to make the outside world understand you.

What overseas companies and investors really want to know is: Why is this city worth visiting? Why can this industrial park accommodate production? Are the policies and services predictable? After bringing technology, capital, and teams, can companies actually make things work?

For overseas biomedical companies, the Chinese market remains indispensable, but the barriers to entry are becoming increasingly clear. Products must adapt to Chinese clinical needs, registration must comply with Chinese regulations, the supply chain must be localized, and services must keep pace with hospitals and patients. What they need is not just an office address, but a foothold that can help them understand the Chinese market and establish local production and service capabilities.

For Chinese domestic medical device companies preparing to go global, internationalization is no longer just about attending a few overseas exhibitions and obtaining a few certifications. For products to go global, the domestic industrial foundation must first be firmly established. Stable production, quality systems, cost structures, supply chain auditing, traceability capabilities, and after-sales service are all issues that must be addressed before venturing overseas.

From this perspective, Changsha and Xiangjiang New Area don't need to portray themselves as low-cost alternatives to coastal cities. The word "alternative" is too simplistic and easily drags the city into price competition. Instead, they should emphasize a new capacity to absorb new businesses: those that need to move from R&D to production, from high-cost regions to a more balanced cost structure, and from single-product offerings to system-wide delivery.

What Yunke Zhigu wants to tell is this story.

Can an industrial park become a stepping stone for industry?

The worst thing for an industrial park is to present itself only as a building.

No matter how new a building is, it will become old in a few years; no matter how low the price is, there will always be someone who will go even lower. What truly retains businesses are those less glamorous things that work every day: someone who understands the process when applying for approvals, someone who knows where the pitfalls are when making renovations, someone who helps them find talent when they are short of staff, someone who helps them connect with financial institutions when they are short of funds, someone who reminds them to prepare materials when policy opportunities open, and someone who provides the next step in the industrial park when they expand production.

These things may seem small, but they represent a company's deepest trust in a place.

Whether it's healthcare sovereignty or industrial upgrading, these concepts cannot remain mere grand pronouncements. They must be grounded in a production line, a laboratory, a cleanroom, a registration certificate, and a stable supply of products. Without these concrete and silent supports, even the grandest industrial blueprints easily remain unrealized.

The value of Golden Innovation Park lies in its incubation and enterprise service capabilities accumulated over the years; the value of Yunke Zhigu lies in its attempt to extend these capabilities to more demanding scenarios such as pharmaceutical intelligent manufacturing and medical device industrialization.

Whether this path is viable still needs to be proven by real-world business cases. Standing beside the right industry issues is just the beginning. The real test is whether we can transform investment pitches on ceiling height, load-bearing capacity, cleanliness, environmental impact assessments, policies, finance, and services into tangible deliverables that businesses can perceive.

For companies looking for a location, a factory is certainly important. But even more important than a factory is whether the location can save the company time, effort, and potential pitfalls.

This is the true meaning of "industrial development should not be about finding factory buildings".

This is also the part that should be most noticed when Changsha, Xiangjiang New Area, Golden Innovation Park, and Yunke Zhigu are attracting investment from around the world.

——

This article is part of the "Medical Sovereignty" series of analyses by the GFM Institutional Observation Research Group. It takes a global perspective on the industrialization of the biomedical industry and focuses on the institutional construction of the biomedical industry infrastructure and industrial implementation system in central China.